You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

niraparib

Showing 26 - 50 of 113
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma Trial in Oklahoma City (Niraparib)

Recruiting
  • Recurrent Glioblastoma
  • +3 more
  • Niraparib
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Jul 20, 2022

Breast Cancer Trial (Niraparib, Doxorubicin, Cyclophosphamide)

Withdrawn
  • Breast Cancer
  • Niraparib
  • +5 more
  • (no location specified)
Apr 20, 2022

Tumors Trial in United States (Niraparib, Pembrolizumab, TSR-042 (Dostarlimab))

Completed
Has Results
  • Neoplasms
  • Niraparib
  • +2 more
  • Whittier, Alaska
  • +15 more
Aug 29, 2022

Tumors Trial in France, Spain, United Kingdom (Niraparib, Dostarlimab)

Recruiting
  • Neoplasms
  • Brno, Czechia
  • +20 more
Nov 21, 2022

Metastatic Colorectal Cancer Trial (Niraparib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Niraparib
  • (no location specified)
Jun 7, 2022

Epithelial Ovarian Cancer Trial (Niraparib)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Niraparib
  • (no location specified)
May 19, 2022

Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer Trial in United States (Niraparib, Dostarlimab)

Recruiting
  • Stage I Breast Cancer
  • +7 more
  • Baltimore, Maryland
  • +6 more
Nov 11, 2022

Sarcoma,Soft Tissue, Sarcoma Uterus Trial in United States (Niraparib)

Recruiting
  • Sarcoma,Soft Tissue
  • Sarcoma Uterus
  • Niraparib
  • Basking Ridge, New Jersey
  • +6 more
Aug 23, 2022

SCLC,Extensive Stage, SLFN11-positive Trial in Worldwide (Niraparib)

Not yet recruiting
  • SCLC,Extensive Stage
  • SLFN11-positive
  • Niraparib
  • Angers, France
  • +19 more
Jan 30, 2023

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Ovarian Cancer Trial in Boston, Copenhagen (Niraparib, Bevacizumab)

Completed
  • Ovarian Cancer
  • Boston, Massachusetts
  • +1 more
Jan 7, 2022

Ovarian Tumors, Breast Tumors Trial in Worldwide (Niraparib)

Active, not recruiting
  • Ovarian Neoplasms
  • Breast Neoplasms
  • Niraparib
  • Tucson, Arizona
  • +22 more
Jul 20, 2022

Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma

Recruiting
  • Recurrent Ovarian Cancer
  • +6 more
  • Oregovomab
  • Niraparib
  • Durham, North Carolina
  • +2 more
Jul 26, 2022

Metastatic Cancer, CNS Cancer Trial in Boston (Niraparib)

Recruiting
  • Metastatic Cancer
  • Central Nervous System Cancer
  • Niraparib
  • Boston, Massachusetts
  • +2 more
Jan 28, 2022

Tumors, Metastatic Cancer, Advanced Cancer Trial in United States (Niraparib, TSR-042, Carboplatin-Paclitaxel)

Active, not recruiting
Has Results
  • Neoplasms
  • +6 more
  • Niraparib
  • +6 more
  • Scottsdale, Arizona
  • +7 more
Oct 31, 2022

Advanced Solid Tumors Trial in Chuo-ku (Niraparib)

Completed
Has Results
  • Advanced Solid Tumors
  • Niraparib
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital
Oct 12, 2021

Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma Trial in United States (Niraparib)

Recruiting
  • Endometrial Cancer
  • +4 more
  • Niraparib
  • New Brunswick, New Jersey
  • +4 more
Mar 17, 2022

Metastatic Melanoma Trial in San Francisco (Niraparib)

Recruiting
  • Metastatic Melanoma
  • Niraparib
  • San Francisco, California
    California Pacific Medical Center Research Institute
Oct 15, 2021

Ovarian Carcinosarcoma, Endometrial Carcinosarcoma Trial in France (Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy

Recruiting
  • Ovarian Carcinosarcoma
  • Endometrial Carcinosarcoma
  • Niraparib
  • +2 more
  • Angers, France
  • +19 more
Feb 23, 2022

Epithelial Ovarian Cancer, Ovarian Cancer, Ovarian Cancer Stage III Trial (Niraparib)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • +3 more
  • Niraparib
  • (no location specified)
Jan 10, 2022

Platinum-resistant Recurrent Clear Cell Ovarian Cancer Trial in Guangzhou (Niraparib, Anlotinib)

Not yet recruiting
  • Platinum-resistant Recurrent Clear Cell Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 21, 2021

Glioblastoma, Glioblastoma Multiforme, Glioma Trial in Phoenix, San Francisco (Niraparib, Radiation therapy)

Recruiting
  • Glioblastoma
  • +5 more
  • Niraparib
  • Radiation therapy
  • Phoenix, Arizona
  • +1 more
Dec 7, 2021

Pancreatic Cancer, Metastatic Pancreatic Cancer Trial in Boston (Niraparib, Dostarlimab, Radiation)

Active, not recruiting
  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Niraparib
  • +2 more
  • Boston, Massachusetts
  • +2 more
Oct 18, 2021

Breast Cancer, Triple Negative Breast Cancer Trial in Washington, Boston, Chapel Hill (Niraparib, Dostarlimab, Radiation

Recruiting
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Niraparib
  • +2 more
  • Washington, District of Columbia
  • +2 more
Apr 13, 2022

Triple Negative Breast Cancer, Residual Disease Trial in Boston (Niraparib, Radiation Therapy)

Recruiting
  • Triple Negative Breast Cancer
  • Residual Disease
  • Niraparib
  • Radiation Therapy
  • Boston, Massachusetts
  • +1 more
Oct 27, 2021